Jade Biosciences, Inc.: Guggenheim cuts target price to $41 from $47
JBIO•Guggenheim cut its target price for Jade Biosciences to $41 from $47.
Related News

Hyperscale Data raises third-quarter revenue estimate to about $45 million from $40 million
GPUS•

Studio City director Lawrence Yau Lung Ho reports $30,904.1544 share acquisition
MSC•

Cellyan Biotechnology regains compliance with Nasdaq minimum bid price requirement
HKPD•

Rivian: Citigroup cuts target price to $14.5 from $18
RIVN•

Quality Industrial reports third-quarter 2026 results
QIND•